

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: TBD

GOFF et al.

APPLICATION NO: TBA

FILED: Concurrently herewith

FOR: CONTROL OF GENE EXPRESSION IN PLANTS BY RECEPTOR
MEDIATED TRANSACTIVATION IN THE PRESENCE OF A CHEMICAL
LIGAND

Commissioner of Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION


Sir:

The sequence listing of the present application is identical to the sequence listing in parent application no. 09/625,904, filed July 26, 2000.

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the CRF that will be used for the present application. Pursuant to 37 C.F.R. § 1.821(f), Applicants' attorney hereby certifies that the contents of the CRF submitted in parent application no. 09/625,904, filed July 26, 2000, and the paper form sequence listing submitted in the present application are the same. Pursuant to 37 CFR §1.821(e) please use the computer readable form (CRF) in parent application serial no. 09/625,904 for the present application.

Syngenta
Patent Department
P.O. Box 12257
Research Triangle Park, NC 27709-2257
(919) 541-8587
Date: March 21, 2001

Respectfully submitted,



J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: TBD

GOFF et al.

APPLICATION NO: TBA

FILED: Concurrently herewith

FOR: CONTROL OF GENE EXPRESSION IN PLANTS BY RECEPTOR
MEDIATED TRANSACTIVATION IN THE PRESENCE OF A CHEMICAL
LIGAND

Commissioner of Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION


Sir:

The sequence listing of the present application is identical to the sequence listing in parent application no. 09/625,904, filed July 26, 2000.

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the CRF that will be used for the present application. Pursuant to 37 C.F.R. § 1.821(f), Applicants' attorney hereby certifies that the contents of the CRF submitted in parent application no. 09/625,904, filed July 26, 2000, and the paper form sequence listing submitted in the present application are the same. Pursuant to 37 CFR §1.821(e) please use the computer readable form (CRF) in parent application serial no. 09/625,904 for the present application.

Syngenta
Patent Department
P.O. Box 12257
Research Triangle Park, NC 27709-2257
(919) 541-8587
Date: March 21, 2001

Respectfully submitted,



J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Goff, Stephen A
Crossland, Lyle D
Privalle, Laura S
- (ii) TITLE OF INVENTION: Control of Gene Expression in Plants by
Receptor Mediated Transactivation in the Presence of a
Chemical Ligand
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: CIBA-GEIGY Corporation
(B) STREET: 7 Skyline Drive
(C) CITY: Hawthorne
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10532
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30B
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US TBA
(B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Spruill, W. Murray
(B) REGISTRATION NUMBER: 32,943
(C) REFERENCE/DOCKET NUMBER: CGC 1796
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 919-541-8590
(B) TELEFAX: 919-541-8689

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF43"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGCGGATCCT AAACAATGAA GCGGCGCTGG TCGAACAACG GC

42

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF23"

- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGCGGGATCC ATGCGGCCGG AATGCGTCGT CCCG

34

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF42"

- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGCGGATCCA TGGACAAC TG CGACCAGGAC

30

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF37"

- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCGGGATCCC CCACCGTACT CGTCAATTC

29

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide SA115"
- (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTCGAGCTCT CGGATCCTAA AACAATGGCC CCCCCGACCG ATGTC

45

- (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide SF25"
- (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GATCCGACAA GGGTTCAATG CACTTGTC

29

- (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide SF26"
- (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GATCTGACAA GTGCATTGAA CCCTTGTCG

29

- (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide SF30"
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
CGCGGATCCA TGGGTCGCGA TGATCTCTCG CCTTC

35

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..11
(D) OTHER INFORMATION: /note= "polylinker used to link the
C1 transactivation domain to Ecr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
VGSRSRVSSH A

11

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "positive strand
oligonucleotide used to create pSKGAL2.3"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
CGGGGGATCC TAAGTAAGTA AGGTAC

26

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "complementary strand
oligonucleotide used to create pSKGAL2.3"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTTACTTACT TAGGATCCCC

20

09813589-032101